All In Biotech

Drug Trial Radar · NCT03537768

Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg

A Multi-center, Randomized Study of the Efficacy of Ulipristal Acetate (UPA) 30 mg, Levonorgestrel (LNG) 1.5 mg, and LNG 3.0 mg for Emergency Contraception (EC) in Women With Weight ≥ 80 kg

Last checked: Nov 20, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 532 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

532

Actual

Start

Jul 12, 2018

Primary completion

Apr 20, 2022

Study completion Apr 20, 2022

Sponsor

Lead sponsor
Kimberly MyerAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted
May 25, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The proposed research study is a Phase IIb, multi-center, single-blind, randomized study of UPA 30 mg, LNG 1.5 mg and LNG 3.0 mg to evaluate EC effectiveness in women with weight ≥ 80 kg who present within 72 hours of unprotected intercourse.

Conditions

  • Contraception

Interventions

  • Ulipristal AcetateDrug

    UPA Tablet

  • LevonorgestrelDrug

    LNG Tablet

  • LevonorgestrelDrug

    LNG Tablet (x2)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of pregnancies of UPA 30 mg, LNG 1.5 mg and LNG 3.0 mg in women with weight ≥ 80 kg for emergency contraception (within 72 hours of unprotected intercourse).Time frame: 1-3 months

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Essential Access Health

    Los Angeles, California

  • University of California, Davis

    Sacramento, California

  • University of California, San Francisco

    San Francisco, California

  • University of Colorado

    Denver, Colorado

  • University of Hawaii

    Honolulu, Hawaii

  • University of Chicago

    Chicago, Illinois

  • Johns Hopkins Bayview Medical Center

    Baltimore, Maryland

  • Planned Parenthood League of Massachusetts

    Boston, Massachusetts

  • Bellevue Hospital Center

    New York, New York

  • Columbia University

    New York, New York

  • University of Cincinnati-Holmes Hospital

    Cincinnati, Ohio

  • University Hospitals of Cleveland MacDonald Women's Hospital

    Cleveland, Ohio

  • Oregon Health Science University

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Pittsburgh/Magee Women's Hospital

    Pittsburgh, Pennsylvania

  • Women & Infants Hospital of Rhode Island

    Providence, Rhode Island

  • University of Utah

    Salt Lake City, Utah

  • Eastern Virginia Medical School

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.